After graduating from Johns Hopkins Medical School, he trained in internal medicine at John’s Hopkins Hospital, and then completed hematology, medical oncology, and tumor immunology training at the Dana-Farber Cancer Institute. Over the last three decades, he has focused his laboratory and clinical research studies on multiple myeloma. He has developed laboratory and animal models of the tumor in it is microenvironment which have allowed for both identification of novel targets and validation of novel targeted therapies, and has then rapidly translated these studies to clinical trials. His team led both preclinical and clinical studies of the proteasome inhibitor Bortezomib and the immunomodulatory drug lenalidomide, culminating in the rapid FDA approval of these agents for treatment of myeloma and markedly improving patient outcome. His paradigm for identifying and validating targets in the tumor cell and its milieu has already transformed myeloma therapy, and offers great promise for patients with other hematologic malignancies and solid tumors as well.
Dr. Anderson received the Waldenstrom’s award from the International Myeloma Workshop in 2003, the Robert A. Kyle Lifetime Achievement Award from the International Myeloma Foundation in 2005, the Joseph H. Burchenal Award for Clinical Research from the American Association for Cancer Research in 2007, and the William Dameshek Prize for Outstanding Contributions to Hematology from the American Society of Hematology in 2008. He was elected into the Johns Hopkins Society of Scholars in 2009, as well as the Institute of Medicine of the National Academies, as well as the Royal College of Physicians and of Pathologists (UK) in 2010. In 2011 he received the David A. Karnofsky Award from the American Society of Clinical Oncology.